Literature DB >> 32956695

Hemophagocytic Lymphohistiocytosis Associated with Histiocytic Necrotizing Lymphadenitis: A Clinical Study of 13 Children and Literature Review.

Ying Yang1, Hongyun Lian1, Honghao Ma1, Yunze Zhao1, Qing Zhang2, Li Zhang1, Tianyou Wang3, Zhigang Li2, Rui Zhang1.   

Abstract

OBJECTIVE: To analyze the clinical characteristics and prognosis of pediatric hemophagocytic lymphohistiocytosis (HLH) associated with histiocytic necrotizing lymphadenitis (HNL). STUDY
DESIGN: We retrospectively collected the clinical data of all children with HNL-HLH enrolled in Beijing Children's Hospital from 2007 to 2019. The control patients with Epstein-Barr virus-associated HLH and simple HNL (not associated with HLH) were case matched (1:2). The clinical features and prognosis were analyzed by case-control study. Cases of HNL-HLH in the literature were reviewed.
RESULTS: The male-to-female ratio of the 13 patients in our center was 9:4. The mean age of the patients at disease onset was 8.1 ± 1.2 years, younger than that of the 16 patients in the literature (P = .017). Clinical presentations, especially rash and splenomegaly, and laboratory examination of HNL-HLH group were statistically different from Epstein-Barr virus-HLH group, simple HNL group, and patients reported in the literature (P < .05). Three patients were treated with immunosuppressive drugs or chemotherapy owing to poor control of HLH. One patient died, and all 12 remaining patients survived, 2 of which developed autoimmune diseases. Kaplan-Meier survival curves showed no statistical difference among the 3 groups (P > .05).
CONCLUSIONS: HNL-HLH is more common in school- and preschool-age children. Most patients have a favorable prognosis. Some patients suffer from relapses or develop autoimmune diseases. Prolonged follow-up should be carried out for patients with HNL-HLH.
Copyright © 2020. Published by Elsevier Inc.

Entities:  

Keywords:  children; hemophagocytic lymphohistiocytosis; histiocytic necrotizing lymphadenitis; literature review

Year:  2020        PMID: 32956695     DOI: 10.1016/j.jpeds.2020.08.063

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  2 in total

1.  Kikuchi-Fujimoto disease associated with hemophagocytic lymphohistiocytosis following the BNT162b2 mRNA COVID-19 vaccination.

Authors:  Giovanni Caocci; Daniela Fanni; Mariagrazia Porru; Marianna Greco; Sonia Nemolato; Davide Firinu; Gavino Faa; Angelo Scuteri; Giorgio La Nasa
Journal:  Haematologica       Date:  2022-05-01       Impact factor: 9.941

2.  Blood cell and marrow changes in patients with Kikuchi disease.

Authors:  Shan-Chi Yu; Huai-Hsuan Huang; Chun-Nan Chen; Tseng-Cheng Chen; Tsung-Lin Yang
Journal:  Haematologica       Date:  2022-08-01       Impact factor: 11.047

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.